STOCK TITAN

Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ryan Cohlhepp filed a Form 144 reporting sales of Common stock of BCAX. The filing lists multiple dispositions in the past three months with dates, share counts, and aggregate sale amounts. Transactions include 12/15/2025: 12,500 shares for $233,547.50, 01/15/2026: 149 shares for $2,684.98, 01/22/2026: 3,828 shares for $69,295.99, and 02/25/2026: 3,631 shares for $69,132.42.

The filing also shows exercises of stock options settled in cash with issuer deliveries: 05/12/2024: 4,500 shares and 03/03/2026: 12,892 shares. The broker listed is UBS Financial Services, Inc.

Positive

  • None.

Negative

  • None.

Insights

Form 144 discloses proposed or completed sales by an affiliate under Section 15(a) notice requirements.

The entries show multiple dispositions by Ryan Cohlhepp with exact share counts and proceeds: 12,500 shares ($233,547.50) on 12/15/2025 and three smaller trades in 01/202602/2026. These are standard sale notices that signal compliance with resale reporting obligations.

Timing and settlement details are specific to each row; subsequent filings or broker confirmations would record final settlement. Cash-flow treatment and whether all sales were executed versus proposed are not further specified in the excerpt.

Transactions represent insider liquidity events rather than corporate actions; amounts are modest in isolation.

The filing lists option exercises resulting in issuer-delivered common shares on 05/12/2024 (4,500 shares) and 03/03/2026 (12,892 shares). The past-three-month sales aggregate to documented proceeds totaling the sums shown next to each trade date.

These entries do not disclose material corporate developments or changes to business operations; market impact depends on the holder's future disposition decisions and is not specified here.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the Form 144 filed for BCAX disclose about insider sales?

It discloses multiple sales by Ryan Cohlhepp, listing share counts and proceeds for each trade. The filing lists specific transactions: 12,500 shares for $233,547.50 on 12/15/2025 and three trades in January–February 2026 with amounts shown.

Who is the broker listed on the BCAX Form 144 filing?

The broker shown is UBS Financial Services, Inc. with an address at Eleven Madison Avenue, New York. That broker is named in the securities and sales sections of the filing excerpt.

Are there option exercises reported in the BCAX excerpt?

Yes. The excerpt lists cash-settled option exercises delivering issuer common shares on 05/12/2024 (4,500 shares) and 03/03/2026 (12,892 shares). These exercise entries appear alongside the sale records.

How many shares did Ryan Cohlhepp sell on 12/15/2025 per the filing?

The filing reports a sale of 12,500 shares by Ryan Cohlhepp on 12/15/2025 with aggregate proceeds of $233,547.50 as shown in the transaction row.

Does the Form 144 excerpt state whether the listed sales were completed or only proposed?

The excerpt lists transaction dates, share counts, and proceeds but does not explicitly state completion status for each line. Settlement or execution confirmations are not provided within the excerpt.
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

BCAX Latest News

BCAX Latest SEC Filings

BCAX Stock Data

981.69M
51.85M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON